| Trials ID |
Arm 1(platinum‐containing)
|
Arm 2(control)
|
First‐line therapy for > 80% of participants |
Majority participants anthracycline‐naive |
| Regimen A + platinum vs regimen A |
| Bhattacharyya 2009 |
(Endoxan + with 'cisplatinum') |
(Endoxan) |
N |
N |
| Carey 2012 |
C + Cb (Cetuximab + carboplatin) |
C (Cetuximab with carboplatin added after progression) |
N |
N |
| Regimen A + platinum vs regimen B |
| Fan 2012 |
TP (docetaxel + cisplatin) |
TX (docetaxel + capecitabine) |
Y |
N |
| Mustafa 2019 |
(cisplatin + gemcitabine) |
(paclitaxel + gemcitabine) |
Y |
N |
| Han 2018 A |
PCP (placebo + carboplatin/paclitaxel) |
VT (veliparib + temozolomide) |
N |
Unknown |
| Han 2018 B |
VCP (eliparib + carboplatin/paclitaxel) |
VT (veliparib + temozolomide) |
N |
Unknown |
| Stemmler 2011 A |
GemCis (gemcitabine + cisplatin) |
GemVin (gemcitabine + vinorelbine) |
N |
N |
| Stemmler 2011 B |
GemCis (gemcitabine + cisplatin) |
GemCap (gemcitabine + capecitabine) |
N |
N |
| Yardley 2018 A |
nab‐P/C (nab‐paclitaxel + carboplatin) |
nab‐P/G (nab‐paclitaxel + gemcitabine) |
Y |
N |
| Yardley 2018 B |
G/C (gemcitabine + carboplatin) |
nab‐P/G (nab‐paclitaxel + gemcitabine) |
Y |
N |
| Zhang 2018 |
(cisplatin + gemcitabine) |
(paclitaxel + gemcitabine) |
Y |
N |
| Icli 2005 |
Etop + Cis (etoposide + cisplatin) |
P (paclitaxel) |
N |
N |
| Single agent platinum vs regimen C |
| Tutt 2018 |
C (carboplatin) |
D (docetaxel) |
Y |
Y |
